
NYSEHealthcareMedical - Devices
最新数据
US$43.84
+US$1.11 · +2.60%
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
收盘时
US$43.84
+US$1.11 · +2.60%
盘后
US$43.77
−US$0.07 · -0.16%
10月12日 19:44 ET
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
95
深度低估
情绪
77
看涨
风险
50
风险偏高
动量
24
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
日内区间
当前US$43.84
52周区间
当前US$43.84
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 200.74亿 USD | 167.47亿 USD | 142.4亿 USD | 126.82亿 USD | 118.88亿 USD |
| 销货成本 | 62.21亿 USD | 64.8亿 USD | 54.09亿 USD | 49.68亿 USD | 44.27亿 USD |
| 毛利 | 138.53亿 USD | 102.67亿 USD | 88.31亿 USD | 77.14亿 USD | 74.61亿 USD |
| 研究与开发 | 20.52亿 USD | 16.15亿 USD | 14.14亿 USD | 13.23亿 USD | 12.04亿 USD |
| 销售、一般及管理费用 | 68.87亿 USD | 59.84亿 USD | 51.9亿 USD | 45.2亿 USD | 42.86亿 USD |
| 营业费用 | 98.82亿 USD | 76.32亿 USD | 66.5亿 USD | 58.9亿 USD | 55.39亿 USD |
| 利息收入 | — | 1.07亿 USD | 2200万 USD | 1000万 USD | 400万 USD |
| 利息支出 | 3.49亿 USD | 3.87亿 USD | 2.72亿 USD | 4.64亿 USD | 3.49亿 USD |
| 折旧和摊销 | 13.68亿 USD | 12.69亿 USD | 11.96亿 USD | 11.36亿 USD | 10.93亿 USD |
| 营业利润 | 39.71亿 USD | 26.35亿 USD | 21.81亿 USD | 18.24亿 USD | 19.22亿 USD |
| 净利润 | 28.86亿 USD | 18.54亿 USD | 15.93亿 USD | 6.98亿 USD | 10.4亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$62.71
上涨空间 43.04%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2003年11月6日 | 2:1 | — | — |
股票拆分 | 1998年12月1日 | 2:1 | — | — |
已生效 2003年11月6日
2:1
已生效 1998年12月1日
2:1
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T1190.31亿0.09%130.34万亿 JPY0.09%JP¥122,8500.00%
Vanguard Morningstar Total Stock Market ETFVTI22.82亿0.10%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard S&P 500 ETFVOO19.07亿0.11%1.8万亿 USD0.03%US$715.13-0.06%
iShares Core S&P 500 ETFIVV8.24亿0.09%8964.4亿 USD0.03%US$781.44-0.07%
State Street SPDR S&P 500 ETFSPY7.5亿0.09%8216.79亿 USD0.09%US$778.1-0.06%
Vanguard Morningstar Growth ETFVUG4.41亿0.11%3846亿 USD0.03%US$91.64-0.36%
State Street Health Care Select Sector SPDR ETFXLV4.34亿1.00%443.1亿 USD0.08%US$171.99+0.69%
Vanguard Morningstar Value ETFVTV3.43亿0.13%2624亿 USD0.03%US$221.43+0.38%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Growth ETFVUG
State Street Health Care Select Sector SPDR ETFXLV
Vanguard Morningstar Value ETFVTVAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。